期刊
MOLECULAR THERAPY-NUCLEIC ACIDS
卷 29, 期 -, 页码 204-216出版社
CELL PRESS
DOI: 10.1016/j.omtn.2022.06.008
关键词
-
资金
- NIH [R01HL123804, R56HL141206-01]
- American Lung Association Biomedical Research Award [RG-416135]
- American Heart Association Career Development Award [18CDA34110301]
- Gilead Sciences Research Scholars Program in Pulmonary Arterial Hypertension
- Chicago Biomedical Consortium Catalyst Award
- NCATS [UL1TR002003]
MicroRNA miR-212-5p has been identified as an anti-proliferative miRNA that is induced in pulmonary artery smooth muscle cells and lungs of pulmonary hypertension patients and experimental animals. It acts as an endogenous inhibitor of pulmonary hypertension by suppressing smooth muscle cell proliferation. In addition, engineered endothelium-derived extracellular vesicles carrying miR-212-5p have shown potential as a delivery system for treating severe pulmonary hypertension.
MicroRNAs (miRNA, miR-) play important roles in disease development. In this study, we identified an anti-proliferative miRNA, miR-212-5p, that is induced in pulmonary artery smooth muscle cells (PASMCs) and lungs of pulmonary hypertension (PH) patients and rodents with experimental PH. We found that smooth muscle cell (SMC)-specific knockout of miR-212-5p exacerbated hypoxia-induced pulmonary vascular remodeling and PH in mice, suggesting that miR-212-5p may be upregulated in PASMCs to act as an endogenous inhibitor of PH, possibly by suppressing PASMC proliferation. Extracellular vesicles (EVs) have been shown recently to be promising drug delivery tools for disease treatment. We generated endothelium-derived EVs with an enriched miR-212-5p load, 212-eEVs, and found that they significantly attenuated hypoxia-induced PH in mice and Sugen/hypoxia-induced severe PH in rats, providing proof of concept that engineered endothelium-derived EVs can be used to deliver miRNA into lungs for treatment of severe PH.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据